P
Petra Korpisalo
Researcher at University of Eastern Finland
Publications - 28
Citations - 1470
Petra Korpisalo is an academic researcher from University of Eastern Finland. The author has contributed to research in topics: Angiogenesis & Vascular endothelial growth factor. The author has an hindex of 19, co-authored 28 publications receiving 1338 citations.
Papers
More filters
Journal ArticleDOI
Vascular Endothelial Growth Factor-B Induces Myocardium-Specific Angiogenesis and Arteriogenesis via Vascular Endothelial Growth Factor Receptor-1– and Neuropilin Receptor-1–Dependent Mechanisms
Johanna Lähteenvuo,Markku Lähteenvuo,Antti Kivelä,Carolina Rosenlew,Annelie Falkevall,Joakim Klar,Tommi Heikura,Tuomas T. Rissanen,Elisa Vähäkangas,Petra Korpisalo,Berndt Enholm,Peter Carmeliet,Kari Alitalo,Ulf Eriksson,Seppo Ylä-Herttuala +14 more
TL;DR: Tissue-specificity, high efficiency in ischemic myocardium, and induction of arteriogenesis and antiapoptotic and metabolic effects make AdVEGF-B186 a promising candidate for the treatment of myocardial ischemia.
Journal ArticleDOI
Vascular Endothelial Growth Factor-B Acts as a Coronary Growth Factor in Transgenic Rats Without Inducing Angiogenesis, Vascular Leak, or Inflammation
Maija Bry,Riikka Kivelä,Tanja Holopainen,Andrey Anisimov,Tuomas Tammela,Jarkko Soronen,Johanna M. U. Silvola,Antti Saraste,Michael Jeltsch,Petra Korpisalo,Peter Carmeliet,Karl B. Lemström,Masabumi Shibuya,Seppo Ylä-Herttuala,Leena Alhonen,Eero Mervaala,Leif C. Andersson,Juhani Knuuti,Kari Alitalo +18 more
TL;DR: In rats, the heart-specific VEGF-B transgene induced impressive growth of the epicardial coronary vessels and their branches, with large arteries also seen deep inside the subendocardial myocardium, however, VEGf-B, unlike other V EGF family members, did not induce significant capillary angiogenesis, increased permeability, or inflammatory cell recruitment.
Journal ArticleDOI
Angiogenic gene therapy in cardiovascular diseases: dream or vision?
TL;DR: The concept of angiogenic therapy as a sole treatment is re-evaluated and a combination with regenerative therapies or standard revascularization operations might be needed to improve tissue function and clinical benefits.
Journal ArticleDOI
Stabilized HIF-1α is superior to VEGF for angiogenesis in skeletal muscle via adeno-associated virus gene transfer
Katri Pajusola,Jaana Künnapuu,Sanna Vuorikoski,Jarkko Soronen,Helder André,Teresa Pereira,Petra Korpisalo,Seppo Ylä-Herttuala,Lorenz Poellinger,Kari Alitalo +9 more
TL;DR: The results show that AAV‐mediated transduction of a stabilized form of HIF‐1 α can circumvent the problems associated with overexpression of individual angiogenic growth factors, and should offer a potent alternative for pro‐angiogenic gene therapy.
Journal ArticleDOI
Efficient Regulation of VEGF Expression by Promoter-Targeted Lentiviral shRNAs Based on Epigenetic Mechanism. A Novel Example of Epigenetherapy
Mikko P. Turunen,Tiia Lehtola,Suvi E. Heinonen,Genet S. Assefa,Petra Korpisalo,Roseanne Girnary,Christopher K. Glass,Sami Väisänen,Seppo Ylä-Herttuala +8 more
TL;DR: It is shown that lentivirus-mediated delivery of shRNA molecules targeted to specific regions in the mVEGF-A promoter either induce or repress VEGF-A expression via epigenetic modulation, describing a new approach of gene therapy, epigenetherapy, based on an epigenetic mechanism at the promoter level.